TARS: חובות מצטברים של החברה Tarsus Pharmaceuticals, Inc.

By leveraging external manufacturing capacities in the US, Tarsus Pharmaceuticals (TARS) is optimizing the production of ophthalmological agents. The volume of credit obligations as of the data snapshot on the GURU.Markets chart shows that 0.10 represents the latest level. Growth is driven by Xdemvy sales and the development of treatments for Lyme disease, while certified GMP lines maintain stable drug output.

Stable revenue from sales of the drug against demodex blepharitis has allowed Tarsus Pharmaceuticals (TARS) to optimize capital expenditure and stabilize liquidity. By aggregating short-term and long-term liabilities, this indicator assesses the total debt load, which, combined with the company's credit portfolio dynamics, helps investors determine business resilience and the risk of asset freezes when analyzing cash flows.